Editas Medicine, Inc. Common Stock
EDITStock
$2.88+10.55%52W
Market Cap$435.06M
P/E—
Div yield—
Beta2.08
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)31.28%
Price vs S&P 500 (4W)28.22%
VGM Score36.11
Market Capitalization$435.06M
Earnings Surprise History
Q1 26-0.26est. -0.27
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.70
3.75
3.75
3.79
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EDITEditas Medicine, Inc. Common Stock | D | D | C | $2.88 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Editas Medicine is a clinical-stage genome editing company developing CRISPR/Cas9-based therapeutics to treat serious genetic diseases. The company's proprietary platform uses a Cas9 enzyme-guide RNA complex to precisely repair disease-causing DNA mutations. Editas is advancing a pipeline of genome editing programs toward clinical and commercial applications.